Table 2.
Encapsulation efficiency (E.E.), drug content (D.C.), and yield percentage of CH/SBE-β-CD NPs and CH/TPP NPs loading LVF.
| NPs Sample * | LVF Theoretical Amount (mg) | Yield (%) ± S.D. | E.E. (%) ± S.D. | D.C. (%) ± S.D. |
|---|---|---|---|---|
| Empty CH/TPP | - | 82.00 ± 4.21 | - | - |
| LVF–CH/TPP2 | 2 | 82.67 ± 5.49 | 21.53 ± 1.47 | 3.47 ± 1.61 |
| LVF–CH/TPP3 | 3 | 82.5 ± 3.48 | 25.33 ± 1.24 | 5.75 ± 1.40 |
| Empty CH/SBE-β-CD | - | 79.62 ± 7.37 | - | - |
| LVF–CH/SBE-β-CD2 | 2 | 81.05 ± 6.53 | 41.50 ± 1.19 | 5.38 ± 1.77 |
| LVF–CH/SBE-β-CD3 | 3 | 81.01 ± 8.51 | 47.83 ± 2.20 | 8.65 ± 2.33 |
* The amount of CH is always 10 mg. The amount of polyanion is 3 mg for TPP and 7.5 mg for SBE-β-CD. The number as subscript of NPs acronyms indicates the theoretical amount of LVF in mg (2 mg or 3 mg). LVF was added to CH solutions for the preparation of CH/TPP NPs and to SBE-β-CD for the preparation of CH/SBE-β-CD NPs. The final volume was maintained at 8 mL for all formulations.